Ironwood director Andrew Dreyfus to resign Nov. 1

Ironwood Pharmaceuticals, Inc. reported that Andrew Dreyfus has notified the company of his resignation from its Board of Directors.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Ironwood Pharmaceuticals, Inc. reported that Andrew Dreyfus has notified the company of his resignation from its Board of Directors. His resignation is effective November 1, 2025.

The company explains that Mr. Dreyfus is stepping down because he has been appointed President and Chief Executive Officer of the National Institute for Health Care Management (NIHCM) Foundation. It states that his decision to resign is not due to any disagreement with Ironwood regarding its operations, policies, or practices.

Ironwood expresses appreciation for Mr. Dreyfus’s service and notes his contributions during his tenure on the Board of Directors.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Andrew Dreyfus resign from Ironwood Pharmaceuticals (IRWD)'s Board of Directors?

Andrew Dreyfus resigned from Ironwood Pharmaceuticals’ Board because he was appointed President and Chief Executive Officer of the National Institute for Health Care Management (NIHCM) Foundation.

When is Andrew Dreyfus’s resignation from IRWD’s Board effective?

Andrew Dreyfus’s resignation from Ironwood Pharmaceuticals’ Board of Directors is effective on November 1, 2025.

Did Andrew Dreyfus have any disagreement with Ironwood Pharmaceuticals (IRWD) leading to his resignation?

The company states that Andrew Dreyfus’s decision to resign was not the result of any disagreement with Ironwood Pharmaceuticals regarding its operations, policies, or practices.

What new role is Andrew Dreyfus taking after leaving Ironwood Pharmaceuticals (IRWD)?

After leaving Ironwood Pharmaceuticals’ Board, Andrew Dreyfus is becoming President and Chief Executive Officer of the National Institute for Health Care Management (NIHCM) Foundation.

How did Ironwood Pharmaceuticals (IRWD) respond to Andrew Dreyfus’s resignation?

Ironwood Pharmaceuticals thanked Andrew Dreyfus for his service and acknowledged the many contributions he made during his tenure on the Board of Directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/10/2025 - 07:05 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to

Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

October 7, 2025

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-34620	04-3404176

(State or other jurisdiction		(I.R.S. Employer
of incorporation)	(Commission File Number)	Identification Number)

100 Summer Street, Suite 2300
Boston, Massachusetts				02110

(Address of principal
executive offices)				(Zip code)

(617) 621-7722

(Registrant’s telephone number,

including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, $0.001 par value	IRWD	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 7, 2025, Andrew Dreyfus provided notice of his resignation from the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”), effective November 1, 2025. Mr. Dreyfus’ decision to resign is due to his appointment as President and Chief Executive Officer of the National Institute for Health Care Management (NIHCM) Foundation and was not a result of any disagreement with the Company or any matter relating to the Company’s operations, policies or practices. The Company thanks Mr. Dreyfus for his service and the many contributions he made to the Company during his tenure on the Board of Directors.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Ironwood Pharmaceuticals, Inc.

Dated: October 10, 2025	By:	/s/ Gregory Martini
		Name: Gregory Martini
		Title: Senior Vice President, Chief Financial Officer

Source: View Original Filing on SEC EDGAR